Nov 1 (Reuters) - Resverlogix Corp RVX.TO
* Resverlogix announces fifth positive recommendation from Data Safety Monitoring Board for phase 3 study of Apabetalone
* Resverlogix - independent DSMB recommended phase 3 study of Apabetalone should continue as planned without modifications
* Resverlogix Corp - full enrollment for phase 3 study of apabetalone now anticipated in first half of 2018